This document is an excerpt from the EUR-Lex website
Document 62007CB0450
Joined Cases C-450/07 and C-451/07: Order of the Court (Seventh Chamber) of 9 November 2009 (References for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio (Italy)) — Roche SpA (C-450/07), Federazione nazionale unitaria dei Titolari di Farmacia italiani (Federfarma) (C-451/07) v Agenzia Italiana del Farmaco (AIFA), Ministero della Salute (First subparagraph of Article 104(3) of the Rules of Procedure — Directive 89/105/EEC — Transparency of measures regulating the prices of medicinal products for human use — Article 4 — Price freeze — Price reduction)
Joined Cases C-450/07 and C-451/07: Order of the Court (Seventh Chamber) of 9 November 2009 (References for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio (Italy)) — Roche SpA (C-450/07), Federazione nazionale unitaria dei Titolari di Farmacia italiani (Federfarma) (C-451/07) v Agenzia Italiana del Farmaco (AIFA), Ministero della Salute (First subparagraph of Article 104(3) of the Rules of Procedure — Directive 89/105/EEC — Transparency of measures regulating the prices of medicinal products for human use — Article 4 — Price freeze — Price reduction)
Joined Cases C-450/07 and C-451/07: Order of the Court (Seventh Chamber) of 9 November 2009 (References for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio (Italy)) — Roche SpA (C-450/07), Federazione nazionale unitaria dei Titolari di Farmacia italiani (Federfarma) (C-451/07) v Agenzia Italiana del Farmaco (AIFA), Ministero della Salute (First subparagraph of Article 104(3) of the Rules of Procedure — Directive 89/105/EEC — Transparency of measures regulating the prices of medicinal products for human use — Article 4 — Price freeze — Price reduction)
OJ C 51, 27.2.2010, p. 12–13
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
27.2.2010 |
EN |
Official Journal of the European Union |
C 51/12 |
Order of the Court (Seventh Chamber) of 9 November 2009 (References for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio (Italy)) — Roche SpA (C-450/07), Federazione nazionale unitaria dei Titolari di Farmacia italiani (Federfarma) (C-451/07) v Agenzia Italiana del Farmaco (AIFA), Ministero della Salute
(Joined Cases C-450/07 and C-451/07) (1)
(First subparagraph of Article 104(3) of the Rules of Procedure - Directive 89/105/EEC - Transparency of measures regulating the prices of medicinal products for human use - Article 4 - Price freeze - Price reduction)
2010/C 51/19
Language of the case: Italian
Referring court
Tribunale Amministrativo Regionale del Lazio
Parties to the main proceedings
Applicant: Roche SpA
Defendants: Agenzia Italiana del Farmaco (AIFA), Ministero della Salute
Re:
Reference for a preliminary ruling — Tribunale Amministrativo Regionale del Lazio — Interpretation of Article 4(1) and (2) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems (OJ 1989 L 40, p. 8) — Price freeze imposed on medicinal products — Procedures to follow in the case of a price reduction
Operative part
1. |
Article 4(1) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems is to be interpreted as meaning that, provided the requirements laid down by that provision are met, the competent authorities of a Member State may adopt general measures reducing the prices of all, or of certain categories of, medicinal products, even if the adoption of those measures is not preceded by a freeze on those prices. |
2. |
Article 4(1) of Directive 89/105 is to be interpreted as meaning that, provided the requirements laid down by that provision are met, the adoption of measures reducing the prices of all, or of certain categories of, medicinal products is possible more than once a year and for several years. |
3. |
Article 4(1) of Directive 89/105 is to be interpreted as meaning that it does not preclude measures controlling the prices of all, or of certain categories of, medicinal products from being adopted on the basis of predicted expenditure, provided that the requirements laid down by that provision are met and that the predictions are based on objective and verifiable data. |
4. |
Article 4(1) of Directive 89/105 is to be interpreted as meaning that it is for the Member States to determine, in compliance with the objective of transparency pursued by that directive and the requirements laid down by that provision, the criteria on the basis of which the review of the macro-economic conditions referred to in that provision is to be conducted and that those criteria may consist in pharmaceutical expenditure alone, in health expenditure overall or even in other types of expenditure. |
5. |
Article 4(2) of Directive 89/105 is to be interpreted as meaning that:
|